Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics Inc (LRMR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.207x
Based on the latest financial reports, Larimar Therapeutics Inc (LRMR) has a cash flow conversion efficiency ratio of -0.207x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.75 Million) by net assets ($139.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Larimar Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Larimar Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Larimar Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Larimar Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hutchison Telecommunications Hong Kong Holdings Limited
F:4C6
|
0.031x |
|
MARUDAI FOOD
F:MFL1
|
N/A |
|
Haitian Water Group Co.Ltd
SHG:603759
|
-0.068x |
|
Tasmea Ltd
AU:TEA
|
0.123x |
|
Lungteh Shipbldg Co Ltd
TW:6753
|
-0.057x |
|
BELLUNA CO. LTD
F:73L
|
N/A |
|
Caribbean Utilities Company Ltd
PINK:CUPUF
|
0.063x |
|
Max Estates Limited
NSE:MAXESTATES
|
0.047x |
Annual Cash Flow Conversion Efficiency for Larimar Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Larimar Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $171.81 Million | $-70.76 Million | -0.412x | -0.59% |
| 2023-12-31 | $81.72 Million | $-33.46 Million | -0.409x | -64.71% |
| 2022-12-31 | $110.90 Million | $-27.57 Million | -0.249x | +61.97% |
| 2021-12-31 | $64.41 Million | $-42.10 Million | -0.654x | -38.94% |
| 2020-12-31 | $89.69 Million | $-42.20 Million | -0.470x | -101.44% |
| 2019-12-31 | $-694.00K | $-22.70 Million | 32.707x | +6025.11% |
| 2018-12-31 | $93.27 Million | $-51.49 Million | -0.552x | +1.39% |
| 2017-12-31 | $78.22 Million | $-43.78 Million | -0.560x | -31.10% |
| 2016-12-31 | $121.73 Million | $-51.98 Million | -0.427x | -21.25% |
| 2015-12-31 | $169.11 Million | $-59.55 Million | -0.352x | -30.24% |
| 2014-12-31 | $104.44 Million | $-28.24 Million | -0.270x | +36.52% |
| 2013-12-31 | $35.22 Million | $-15.00 Million | -0.426x | +74.75% |
| 2012-12-31 | $8.06 Million | $-13.59 Million | -1.687x | -- |